Clinical Trial Update: Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and tolerability of dabigatran etexilate oral solution in children aged 1 to under 12 with venous thromboembolism; results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Venous Thromboembolism | Phase 2 | Status: COMPLETED | Results posted: 2016-12-28